Atezolizumab - Genentech

Drug Profile

Atezolizumab - Genentech

Alternative Names: Anti-PDL-1-Genentech/Roche; MPDL-3280A; RG-7446; RO-5541267; TECENTRIQ

Latest Information Update: 08 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer Amgen; ARCAGY/GINECO Group; BioLineRx; Chugai Pharmaceutical; Clovis Oncology; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer; Exelixis; Fondazione Michelangelo; Genentech; GERCOR; Gradalis; Immune Design; Incyte Corporation; M. D. Anderson Cancer Center; National Cancer Center (Korea); National Cancer Institute (USA); Netherlands Cancer Institute; Roche; Sanofi; University Hospital Southampton NHS Foundation Trust; University Medical Center Groningen; University of California at San Francisco; University of California System; Yale University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 ligand-1inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Urogenital cancer
  • Phase III Bladder cancer; Breast cancer; Fallopian tube cancer; Head and neck cancer; Hepatocellular carcinoma; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Anal cancer; Brain metastases; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Gynaecological cancer; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Oesophageal cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute myeloid leukaemia; Follicular lymphoma; Glioblastoma; Pancreatic cancer
  • Phase I Multiple myeloma; Non-Hodgkin's lymphoma
  • No development reported Haematological malignancies
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 31 Jul 2018 Roche initiates a phase II trial for Melanoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in Spain (EudraCT2018-000759-41)
  • 26 Jul 2018 Discontinued - Phase-I for Solid tumours (Combination therapy with cobimetinib, Late-stage disease, Metastatic disease) in USA, Germany, Australia, Singapore, South Korea, Canada (IV) (NCT01988896) (Roche pipeline, July 2018)
  • 26 Jul 2018 Discontinued - Phase-III for Colorectal cancer (Combination therapy with cobimetinib, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA, United Kingdom, Spain, Russia, Poland, South Korea, Italy, Hong Kong, Canada, Belgium, Australia (IV) (NCT02788279) (Roche pipeline, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top